Trio Pharmaceuticals develops dual-targeting antibody drugs, TIE-ADC™ and TRAILBody™, that selectively eliminate cancer cells while overcoming tumor immunosuppression, thereby enhancing the immune response without harming healthy cells. This approach addresses the limitations of current cancer therapies, which often lack selectivity and can inadvertently damage normal tissues, leading to significant treatment-related toxicity.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FBFounders
Product
Problem
Current cancer therapies often lack the selectivity needed to target cancer cells effectively, leading to damage of healthy tissues and significant treatment-related toxicity. Furthermore, many cancers suppress the body's immune response, limiting the effectiveness of immunotherapies.
Solution
Trio Pharmaceuticals is developing dual-targeting antibody drugs, TIE-ADC™ and TRAILBody™, designed to selectively eliminate cancer cells while overcoming tumor immunosuppression. TIE-ADC™ (Tumor Immunity Enhancing Antibody-Drug Conjugate™) targets both cancer cells and immunosuppressor cells within the tumor microenvironment, aiming to enhance anti-tumor immune responses. TRAILBody™ directly induces cancer cell death without harming normal cells, offering a potentially non-toxic approach to tumor eradication. These dual-targeting antibodies address limitations of existing cancer treatments by increasing selectivity and enhancing the body's natural immune response.
Target Audience
The primary target audience includes patients with cancers such as AML, MDS, ovarian cancer, endometrial cancer, TNBC, and NSCLC, particularly those who have failed to respond to current treatments.
Features
- TIE-ADC™: A dual-targeting antibody-drug conjugate designed to kill cancer cells and remove immunosuppression within the tumor.
- TRAILBody™: An antibody designed to directly kill cancer cells by activating endogenous cell death pathways, while sparing normal cells.
- Targets highly expressed tumor antigens to improve selectivity and reduce off-target effects.
- Designed to enhance anti-tumor immune response by removing immunosuppression in the tumor microenvironment.
- Potential for use as a first-line treatment or in combination with standard chemotherapy.
- Pipeline includes drug candidates targeting acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), ovarian cancer, endometrial cancer, triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).